Arthritis Mutilans: Case Report of an Uncommon Squeal of Psoriatic Arthritis
Keywords:
Rheumatology, Hand deformity, Psoriasis, Arthritis, JointsAbstract
Psoriatic arthritis (PsA) is a seronegative spondyloarthropathy that presents clinically in different forms. Arthritis mutilans is
a rare yet the most aggressive and disabling form of PsA that requires early diagnosis and aggressive therapy preferably in the
form of biological agents to prevent or stop the irreversible destruction of small joints. We describe here, report of a case of
long standing PsA who developed arthritis mutilans resulting in disability, compromised mobility and a poor quality of life.
References
am. amYoto T. Psoriatic arthritis: from a dermatological perspective. Eur J Dermatol. 2011;21:660-6
Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population- based study. Arthritis Rheum. 2009;61(2):233-9 10.1002/ art.24172. Erratum in: Arthritis Rheum. 2010;62(4):574
Cantini F, Piccoli L, Nannini C, Kaloudi O, Bretoni M, Cassarà E.Psoriatic arthritis: a systematic review. Int J Rheum Dis 2010;13:300-17
Dhir V, Aggarwal A. Psoriatic arthritis: a critical review. Clin Rev Allergy Immunol. 2013; 44 (2):141-8
Rodrigues- Moreno J, Bonet M, Blanco-Barnusell J, Castano C, Clavaguera T,Mteo-Soria L, et al. Mutilating/ resorptive arthritis. A study of 24 patients in a series of 360 patients with psoriatic arthritis. Reumatol Clinic 2013;2013:38-41
Bruzzese V, Marrese C, Ridola L, Zullo A. Psoriatic arthritis mutilans: case series and literature review. J
Rheumatol. 2013;40(7):1233-6
Veale DJ. Psoriatic arthritis: recent progress in pathophysiology and drug development. Arthritis Res Ther. 2013;15(6):224
Eder L, Thavaneswaran A, Chandran V, Gladman DD. Tumour necrosis factor blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis. Ann Rheum Dis. 2014;73(6):1007-11
Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo- Ortega H, van der Heijde D, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012; 71(1):4-12
Kavanaugh A, McInnes I, Mease P, Krueges GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum2009;60:976–86
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Farooq Azam Rathore, Saeed Bin Ayaz
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0 
